
  
    
      
        Background_NNP
        Regular_JJ use_NN of_IN aspirin_NN and_CC other_JJ non-steroidal_JJ
        anti-inflammatory_JJ drugs_NNS (_( NSAIDs_NNP )_) has_VBZ been_VBN consistently_RB
        associated_VBN with_IN reduced_VBN risk_NN of_IN colorectal_NN cancer_NN and_CC
        adenoma_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ,_, and_CC there_EX is_VBZ some_DT evidence_NN for_IN a_DT
        protective_JJ effect_NN for_IN other_JJ types_NNS of_IN cancer_NN [_NN 5_CD 6_CD 7_CD 8_CD 9_CD ]_NN ._.
        It_PRP is_VBZ widely_RB thought_VBN that_IN the_DT mechanism_NN by_IN which_WDT these_DT
        drugs_NNS affect_VBP cancer_NN risk_NN is_VBZ through_IN the_DT inhibition_NN of_IN the_DT
        cyclooxygenase_NN (_( COX_NNP )_) enzymes_NNS :_: the_DT constitutively_RB expressed_VBN
        COX-_NNP 1_CD and_CC the_DT induced_VBN (_( in_IN most_JJS tissues_NNS )_) COX-_NNP 2_CD [_NN 10_CD ]_NN ._. By_IN
        inhibiting_VBG these_DT enzymes_NNS ,_, NSAIDs_NNP can_MD inhibit_VB prostaglandin_NN
        synthesis_NN ,_, enhance_VB cellular_JJ immune_JJ response_NN ,_, or_CC induce_VB of_IN
        apoptosis_NNS ,_, all_DT of_IN which_WDT have_VBP been_VBN postulated_JJ to_TO be_VB involved_VBN
        in_IN carcinogenesis_NNS [_NN 11_CD 12_CD 13_CD ]_NN ._.
        The_DT cyclooxygenase_NN pathway_NN and_CC NSAIDs_NNP have_VBP been_VBN
        implicated_VBN in_IN pancreatic_JJ carcinogenesis_NNS ,_, as_IN elevated_VBD levels_NNS
        of_IN COX-_NNP 2_CD mRNA_NN and_CC protein_NN have_VBP been_VBN detected_VBN in_IN pancreatic_JJ
        carcinomas_NNS relative_JJ to_TO histologically_RB normal_JJ cells_NNS [_NN 14_CD 15_CD
        16_CD 17_CD 18_CD 19_CD ]_NN ._. Further_RB ,_, both_DT aspirin_NN [_NN 20_CD 21_CD 22_CD ]_NN and_CC
        other_JJ NSAIDs_NNP [_NN 19_CD ]_NN have_VBP been_VBN shown_VBN to_TO inhibit_VB pancreatic_JJ
        cancer_NN cell_NN proliferation_NN and_CC induce_VB apoptosis_NNS 
        in_IN vitro_NN ._. Recent_JJ studies_NNS have_VBP also_RB
        reported_VBN an_DT association_NN between_IN oncogenic_JJ 
        ras_NNS and_CC COX-_NNP 2_CD expression_NN [_NN 23_CD 24_CD ]_NN ._.
        Since_IN pancreatic_JJ tumors_NNS tend_VBP to_TO exhibit_VB a_DT high_JJ frequency_NN of_IN
        K-_NNP 
        ras_NNS mutations_NNS [_NN 25_CD ]_NN ,_, the_DT
        relationship_NN between_IN the_DT K-_NNP 
        ras_NNS oncogene_NN and_CC COX-_NNP 2_CD should_MD be_VB
        explored_JJ further_RB in_IN vivo_NN ._. In_IN general_JJ ,_, laboratory_NN findings_NNS
        suggest_VBP that_IN COX_NNP ,_, especially_RB COX-_NNP 2_CD ,_, may_MD provide_VB a_DT potential_JJ
        target_NN for_IN the_DT prevention_NN and_CC possible_JJ treatment_NN of_IN
        pancreatic_JJ cancer_NN ._.
        Few_JJ studies_NNS have_VBP examined_VBN COX_NNP and_CC pancreatic_JJ cancer_NN in_IN
        humans_NNS ,_, whether_IN it_PRP be_VB in_IN clinical_JJ or_CC epidemiological_JJ
        studies_NNS ._. A_DT recent_JJ study_NN did_VBD not_RB demonstrate_VB an_DT association_NN
        between_IN COX-_NNP 2_CD expression_NN and_CC pathological_JJ or_CC clinical_JJ
        factors_NNS ,_, such_JJ as_IN age_NN ,_, gender_NN ,_, survival_NN ,_, tumor_NN size_NN ,_, stage_NN
        and_CC vascular_NN invasion_NN [_NN 26_CD ]_NN ,_, confirming_VBG results_NNS reported_VBD
        in_IN previous_JJ studies_NNS [_NN 14_CD 17_CD 22_CD ]_NN ._. To_TO our_PRP$ knowledge_NN ,_, only_RB
        three_CD population_NN studies_NNS ,_, with_IN varying_VBG methodological_JJ
        rigor_NN ,_, have_VBP been_VBN published_VBN examining_VBG the_DT relationship_NN
        between_IN NSAID_NNP use_NN and_CC pancreatic_JJ cancer_NN [_NN 27_CD 28_CD 29_CD ]_NN ._. Each_DT
        of_IN these_DT studies_NNS reported_VBD a_DT lack_NN of_IN association_NN ._. However_RB ,_, a_DT
        recently_RB published_VBN report_NN on_IN this_DT association_NN ,_, based_VBN on_IN a_DT
        prospective_JJ cohort_NN of_IN 28_CD ,_, 283_CD post-menopausal_JJ women_NNS ,_,
        described_VBD a_DT trend_NN of_IN decreasing_VBG risk_NN of_IN pancreatic_JJ cancer_NN
        with_IN increased_VBN weekly_JJ aspirin_NN use_NN [_NN 30_CD ]_NN ._.
        In_IN light_NN of_IN the_DT laboratory_NN evidence_NN and_CC limited_JJ number_NN
        population-based_JJ studies_NNS ,_, we_PRP conducted_VBD a_DT hospital-based_JJ
        case-control_JJ study_NN to_TO further_VB investigate_VB the_DT association_NN
        between_IN regular_JJ aspirin_NN use_NN and_CC the_DT risk_NN of_IN pancreatic_JJ
        cancer_NN ._.
      
      
        Methods_NNP
        The_DT study_NN population_NN included_VBD men_NNS and_CC women_NNS seen_VBN at_IN the_DT
        Roswell_NNP Park_NNP Cancer_NNP Institute_NNP (_( RPCI_NNP )_) between_IN 1982_CD and_CC 1998_CD
        who_WP completed_VBD a_DT comprehensive_JJ epidemiological_JJ
        questionnaire_NN ._. Informed_NNP consent_NN was_VBD obtained_VBN from_IN all_DT
        participants_NNS ._. The_DT case_NN group_NN was_VBD comprised_VBN of_IN 194_CD
        predominantly_RB Caucasian_NNP (_( 96_CD ._. 6_CD %_NN )_) patients_NNS with_IN pancreatic_JJ
        cancer_NN identified_VBN from_IN the_DT Roswell_NNP Park_NNP Cancer_NNP Institute_NNP
        tumor_NN registry_NN and_CC diagnostic_JJ index_NN ,_, ranging_VBG in_IN age_NN from_IN 30_CD
        to_TO 84_CD years_NNS ._. Similarly_RB ,_, the_DT control_NN group_NN included_VBD 582_CD men_NNS
        and_CC women_NNS ,_, mostly_RB Caucasian_NNP (_( 94_CD ._. 5_LS %_NN )_) ,_, ranging_VBG in_IN age_NN from_IN 27_CD
        to_TO 85_CD ,_, who_WP received_VBD medical_JJ services_NNS at_IN RPCI_NNP for_IN
        non-neoplastic_JJ conditions_NNS ._. These_DT individuals_NNS came_VBD to_TO RPCI_NNP
        with_IN a_DT suspicion_NN of_IN neoplastic_JJ disease_NN ,_, but_CC were_VBD not_RB
        diagnosed_VBN with_IN malignant_JJ conditions_NNS ._. Controls_NNP were_VBD
        frequency_NN matched_VBN to_TO cases_NNS by_IN sex_NN and_CC five-year_JJ age_NN
        intervals_NNS ._.
        All_DT participants_NNS completed_VBD the_DT Patient_NNP Epidemiology_NNP Data_NNP
        System_NNP (_( PEDS_NNP )_) questionnaire_NN ,_, which_WDT is_VBZ offered_VBN to_TO all_DT new_JJ
        patients_NNS ,_, and_CC returned_VBN by_IN approximately_RB 50_CD %_NN of_IN patients_NNS ._.
        The_DT 16_CD -_: page_NN instrument_NN covers_VBZ information_NN on_IN reproductive_JJ
        and_CC medical_JJ histories_NNS ,_, family_NN history_NN of_IN cancer_NN ,_,
        occupational_NN and_CC environmental_JJ exposures_NNS ,_, tobacco_NN use_NN ,_,
        alcohol_NN consumption_NN ,_, and_CC diet_NN ._. The_DT instrument_NN also_RB assesses_NNS
        aspirin_NN and_CC other_JJ medication_NN use_NN prior_RB to_TO the_DT onset_NN of_IN any_DT
        current_JJ illness_NN ,_, with_IN questions_NNS asking_VBG how_WRB many_JJ times_NNS per_IN
        week_NN the_DT drug_NN was_VBD taken_VBN ,_, number_NN of_IN years_NNS taken_VBN and_CC year_NN of_IN
        first_JJ use_NN ._. For_IN study_NN purposes_NNS ,_, subjects_NNS were_VBD classified_VBN as_IN
        regular_JJ aspirin_NN users_NNS if_IN they_PRP had_VBD taken_VBN the_DT drug_NN at_IN least_JJS
        once_RB a_DT week_NN for_IN at_IN least_JJS one_CD year_NN ,_, and_CC non-users_JJ if_IN they_PRP
        did_VBD not_RB meet_VB both_DT of_IN the_DT conditions_NNS ._. Dosage_NNP of_IN use_NN was_VBD
        assessed_VBN by_IN comparing_VBG non-users_JJ to_TO patients_NNS reporting_VBG they_PRP
        had_VBD taken_VBN aspirin_NN either_CC one_CD to_TO six_CD times_NNS per_IN week_NN or_CC seven_CD
        or_CC more_JJR times_NNS per_IN week_NN ._. Duration_NNP of_IN use_NN was_VBD evaluated_VBN by_IN
        comparing_VBG non-users_JJ to_TO patients_NNS reporting_VBG six_CD months_NNS to_TO ten_CD
        years_NNS of_IN use_NN or_CC more_JJR than_IN ten_CD years_NNS ._. A_DT final_JJ variable_NN ,_,
        termed_VBD "_'' tablet-years_JJ "_'' was_VBD created_VBN that_WDT reflected_VBD both_DT
        duration_NN and_CC frequency_NN of_IN use_NN (_( daily_JJ use_NN ×_NN years_NNS of_IN
        use_NN )_) ._.
        Preliminary_JJ analyses_NNS were_VBD performed_VBN to_TO examine_VB
        descriptive_JJ characteristics_NNS of_IN the_DT pancreatic_JJ cases_NNS and_CC
        hospital_NN controls_NNS ,_, and_CC the_DT association_NN of_IN these_DT
        characteristics_NNS with_IN risk_NN of_IN developing_VBG pancreatic_JJ cancer_NN ._.
        They_PRP consisted_VBD of_IN known_VBN and_CC suspected_VBN risk_NN factors_NNS for_IN
        pancreatic_JJ cancer_NN :_: age_NN ,_, education_NN ,_, cigarette_NN smoking_NN ,_,
        family_NN history_NN of_IN pancreatic_JJ cancer_NN ,_, race_NN ,_, sex_NN and_CC body_NN
        mass_NN index_NN ._. Unconditional_NNP logistic_JJ regression_NN analysis_NN was_VBD
        used_VBN to_TO compute_VB odds_NNS ratios_NNS (_( ORs_NNP )_) with_IN 95_CD %_NN confidence_NN
        intervals_NNS (_( CIs_NNP )_) ._. As_IN packyears_NNS of_IN cigarettes_NNS smoked_VBD smoking_VBG
        (_( packs_NNS per_IN day_NN ×_NN years_NNS of_IN smoking_NN )_) and_CC family_NN history_NN of_IN
        pancreatic_JJ cancer_NN were_VBD found_VBN to_TO be_VB predictors_NNS of_IN disease_NN in_IN
        our_PRP$ data_NNS ,_, they_PRP were_VBD adjusted_VBN for_IN in_IN the_DT regression_NN models_NNS ,_,
        along_IN with_IN age_NN ._. In_IN all_DT analyses_NNS ,_, non-users_JJ of_IN aspirin_NN
        represented_VBD the_DT reference_NN group_NN ._.
      
      
        Results_NNS
        Descriptive_NNP characteristics_NNS of_IN pancreatic_JJ cancer_NN cases_NNS
        and_CC hospital_NN controls_NNS are_VBP shown_VBN in_IN Table_NNP 1_CD ._. Cases_NNS were_VBD more_RBR
        likely_JJ to_TO be_VB smokers_NNS ,_, have_VBP a_DT family_NN history_NN of_IN pancreatic_JJ
        cancer_NN ,_, less_RBR likely_JJ to_TO have_VB schooling_NN beyond_IN high_JJ school_NN ,_,
        and_CC have_VBP a_DT higher_JJR BMI_NNP ._.
        In_IN this_DT study_NN population_NN ,_, approximately_RB 44_CD %_NN of_IN the_DT cases_NNS
        and_CC controls_NNS were_VBD classified_VBN as_IN regular_JJ aspirin_NN users_NNS ._. Risk_NN
        of_IN pancreatic_JJ cancer_NN associated_VBN with_IN aspirin_NN use_NN is_VBZ shown_VBN
        in_IN Table_NNP 2_CD ._. Regular_JJ aspirin_NN use_NN was_VBD not_RB related_VBN to_TO
        pancreatic_JJ cancer_NN risk_NN (_( adjusted_VBN OR_NNP =_SYM 1_CD ._. 00_CD ;_: 95_CD %_NN CI_NNP
        0_CD ._. 72_CD -_: 1_CD ._. 39_CD )_) ._. Increased_VBN weekly_JJ dosage_NN was_VBD not_RB associated_VBN with_IN
        a_DT modification_NN in_IN risk_NN (_( adjusted_VBN OR_NNP =_SYM 0_CD ._. 85_CD ;_: 95_CD %_NN CI_NNP
        0_CD ._. 49_CD -_: 1_CD ._. 45_CD for_IN seven_CD or_CC more_JJR tablets_NNS per_IN week_NN )_) ,_, but_CC a_DT
        non-significant_JJ increase_NN in_IN risk_NN was_VBD observed_VBN for_IN increased_VBN
        duration_NN of_IN use_NN (_( adjusted_VBN OR_NNP =_SYM 1_CD ._. 21_CD ;_: 95_CD %_NN CI_NNP 0_CD ._. 81_CD -_: 1_CD ._. 82_CD for_IN
        11_CD or_CC more_JJR years_NNS of_IN use_NN )_) ._. Over_IN 11_CD tablet-years_JJ of_IN use_NN was_VBD
        associated_VBN with_IN a_DT reduced_VBN risk_NN in_IN the_DT overall_RB set_VBN (_( adjusted_VBN
        OR_NNP =_SYM 0_CD ._. 65_CD 95_CD %_NN CI_NNP 0_CD ._. 37_CD -_: 1_CD ._. 16_CD )_) ,_, although_IN it_PRP must_MD be_VB noted_VBN that_IN
        the_DT 95_CD %_NN confidence_NN interval_NN did_VBD include_VB unity_NN ._. This_DT
        association_NN was_VBD more_RBR pronounced_JJ in_IN men_NNS than_IN women_NNS ._. In_IN
        general_JJ ,_, the_DT risk_NN estimates_NNS and_CC 95_CD %_NN confidence_NN intervals_NNS
        obtained_VBD following_VBG adjustment_NN for_IN smoking_NN and_CC family_NN
        history_NN of_IN pancreatic_JJ cancer_NN were_VBD very_RB similar_JJ to_TO the_DT
        unadjusted_JJ ,_, crude_NN results_NNS ._.
        While_IN stratification_NN based_VBN on_IN sex_NN resulted_VBD in_IN analysis_NN
        of_IN two_CD smaller_JJR data_NNS sets_NNS ,_, results_NNS and_CC direction_NN of_IN point_NN
        estimates_NNS were_VBD generally_RB similar_JJ for_IN men_NNS and_CC women_NNS compared_VBN
        to_TO each_DT other_JJ and_CC the_DT total_JJ set_VBN ._. Analyses_NNS were_VBD also_RB
        performed_VBN after_IN restricting_VBG the_DT sample_NN to_TO individuals_NNS who_WP
        were_VBD at_IN least_JJS 50_CD years_NNS old_JJ ,_, with_IN similar_JJ results_NNS as_IN those_DT
        presented_VBN in_IN Table_NNP 2_CD (_( data_NNS not_RB shown_VBN )_) ._.
      
      
        Discussion_NNP
        Our_PRP$ results_NNS do_VBP not_RB support_VB the_DT notion_NN that_DT aspirin_NN plays_VBZ
        a_DT role_NN in_IN the_DT development_NN of_IN pancreatic_JJ cancer_NN ._. Most_JJS risk_NN
        estimates_NNS were_VBD close_RB to_TO the_DT null_NN ._. Unfortunately_RB ,_, the_DT lack_NN
        of_IN a_DT coherent_JJ pattern_NN or_CC trend_NN in_IN the_DT risk_NN estimates_NNS
        preclude_VB conclusions_NNS based_VBN on_IN integrating_VBG the_DT results_NNS ._.
        Our_PRP$ results_NNS contrast_VBP with_IN those_DT reported_VBN by_IN Anderson_NNP 
        et_CC al_NN ._. [_NN 30_CD ]_NN ,_, who_WP demonstrated_VBD a_DT
        significant_JJ ,_, dose-dependent_JJ ,_, reduced_VBN risk_NN in_IN a_DT cohort_NN of_IN
        28_CD ,_, 283_CD post-menopausal_JJ women_NNS ._. We_PRP observed_VBD a_DT suggestion_NN of_IN
        increased_VBN risk_NN in_IN women_NNS associated_VBN with_IN duration_NN of_IN use_NN ,_,
        but_CC analyses_NNS of_IN cases_NNS by_IN menopausal_NN status_NN were_VBD limited_VBN by_IN
        small_JJ numbers_NNS ._. Further_RB ,_, this_DT non-significant_JJ risk_NN reduction_NN
        is_VBZ difficult_JJ to_TO interpret_VB ,_, due_JJ to_TO the_DT inverse_NN association_NN
        with_IN regular_JJ use_NN and_CC dose_NN in_IN women_NNS ._.
        Three_CD other_JJ studies_NNS have_VBP also_RB examined_VBN NSAID_NNP use_NN and_CC
        pancreatic_JJ cancer_NN risk_NN [_NN 27_CD 28_CD 29_CD ]_NN ._. While_IN these_DT studies_NNS
        had_VBD similar_JJ null_NN results_NNS ,_, they_PRP differed_VBD in_IN their_PRP$ assessment_NN
        of_IN NSAID_NNP use_NN ._. Langman_NNP 
        et_CC al_NN ._. [_NN 29_CD ]_NN used_VBD a_DT general_JJ practice_NN
        research_NN database_NN from_IN the_DT United_NNP Kingdom_NNP that_WDT included_VBD
        data_NNS on_IN morbidity_NN and_CC NSAID_NNP prescriptions_NNS ._. For_IN 12_CD ,_, 174_CD
        incident_NN cancer_NN cases_NNS (_( 396_CD pancreas_NN )_) and_CC 34_CD ,_, 934_CD controls_NNS ,_,
        information_NN on_IN NSAID_NNP prescriptions_NNS for_IN 13_CD -_: 36_CD months_NNS prior_RB
        to_TO cancer_NN diagnosis_NN (_( equivalent_NN information_NN for_IN controls_NNS )_)
        was_VBD extracted_VBN for_IN the_DT period_NN of_IN 1993_CD -_: 1995_CD ._. Associations_NNP
        between_IN risk_NN of_IN cancer_NN and_CC number_NN of_IN prescriptions_NNS were_VBD
        analyzed_VBN ,_, with_IN no_DT association_NN being_VBG found_VBN for_IN pancreatic_JJ
        cancer_NN ._. Gridley_NNP 
        et_CC al_NN ._. [_NN 27_CD ]_NN examined_VBD the_DT incidence_NN
        of_IN cancer_NN among_IN 11_CD ,_, 683_CD Swedish_JJ rheumatoid_NN arthritis_NN
        patients_NNS ,_, testing_VBG the_DT hypothesis_NNS that_IN individuals_NNS who_WP were_VBD
        taking_VBG regular_JJ amounts_NNS of_IN NSAIDs_NNP would_MD have_VB lower_JJR cancer_NN
        rates_NNS ._. Of_IN the_DT 840_CD cancer_NN cases_NNS occurring_VBG from_IN 1965_CD to_TO 1983_CD ,_,
        32_CD had_VBD pancreatic_JJ cancer_NN ._. Using_VBG regional_JJ cancer_NN rates_NNS ,_,
        standardized_JJ incidence_NN ratios_NNS (_( SIR_NNP )_) were_VBD calculated_VBN ._. There_EX
        was_VBD a_DT slightly_RB reduced_VBN risk_NN for_IN pancreatic_JJ cancer_NN ,_, although_IN
        this_DT risk_NN was_VBD not_RB significant_JJ (_( SIR_NNP =_SYM 0_CD ._. 83_CD ,_, 95_CD %_NN CI_NNP 0_CD ._. 6_CD -_: 1_CD ._. 2_LS )_) ._.
        There_EX was_VBD no_DT information_NN on_IN individual_JJ doses_NNS ._. Finally_RB ,_,
        Coogan_NNP 
        et_CC al_NN ._. [_NN 28_CD ]_NN examined_VBD the_DT
        association_NN between_IN NSAID_NNP use_NN and_CC risk_NN of_IN digestive_JJ cancers_NNS
        in_IN a_DT hospital-based_JJ case-control_JJ study_NN ._. Included_VBN in_IN the_DT
        overall_JJ group_NN were_VBD 504_CD pancreatic_JJ cancer_NN patients_NNS and_CC 595_CD
        controls_NNS ._. Defining_VBG regular_JJ NSAID_NNP use_NN as_IN use_NN for_IN at_IN least_JJS
        four_CD days_NNS per_IN week_NN for_IN at_IN least_JJS three_CD months_NNS ,_, initiated_VBN at_IN
        least_JJS one_CD year_NN before_IN hospital_NN admission_NN ,_, they_PRP found_VBD a_DT
        slight_JJ negative_JJ association_NN between_IN NSAID_NNP use_NN and_CC risk_NN of_IN
        pancreatic_JJ cancer_NN (_( continual_JJ vs_NNS ._. never_RB users_NNS OR_NNP =_SYM 0_CD ._. 8_CD ,_, 95_CD %_NN
        CI_NNP 0_CD ._. 5_CD -_: 1_CD ._. 1_LS ;_: use_NN over_IN 5_CD years_NNS vs_NNS ._. never_RB users_NNS OR_NNP =_SYM 0_CD ._. 6_CD ,_, 95_CD %_NN
        CI_NNP 0_CD ._. 4_CD -_: 1_CD ._. 1_LS )_) ._. In_IN general_JJ ,_, while_IN the_DT methodology_NN and_CC exposure_NN
        assessment_NN of_IN these_DT three_CD studies_NNS differed_VBD greatly_RB ,_, a_DT lack_NN
        of_IN association_NN between_IN NSAID_NNP use_NN and_CC pancreatic_JJ cancer_NN risk_NN
        or_CC incidence_NN ,_, as_IN represented_VBN by_IN risk_NN estimates_NNS and_CC
        confidence_NN intervals_NNS ,_, was_VBD reported_VBN ._.
        Our_PRP$ null_NN findings_NNS may_MD be_VB related_VBN to_TO the_DT possibility_NN
        that_IN ,_, prior_RB to_TO cancer_NN diagnosis_NN or_CC because_IN of_IN associated_VBN
        conditions_NNS or_CC complications_NNS ,_, cases_NNS experienced_VBD sufficient_JJ
        discomfort_NN to_TO warrant_VB aspirin_NN usage_NN ._. Unfortunately_RB ,_, reasons_NNS
        for_IN aspirin_NN use_NN were_VBD not_RB available_JJ ._. Exposure_NNP
        misclassification_NN of_IN aspirin_NN use_NN ,_, likely_JJ to_TO be_VB
        non-differential_JJ ,_, may_MD have_VB also_RB caused_VBN attenuation_NN of_IN the_DT
        results_NNS ,_, since_IN the_DT analyses_NNS were_VBD based_VBN on_IN self-reported_JJ
        aspirin_NN use_NN and_CC was_VBD based_VBN on_IN number_NN of_IN pills_NNS taken_VBN ,_, and_CC not_RB
        the_DT actual_JJ dose_NN of_IN aspirin_NN ._. The_DT hospital-based_JJ design_NN ,_,
        although_IN potentially_RB reducing_VBG recall_NN bias_NN ,_, may_MD lessen_VB the_DT
        generalizability_NN of_IN our_PRP$ findings_NNS to_TO the_DT general_JJ population_NN ._.
        However_RB ,_, it_PRP is_VBZ unlikely_JJ that_IN self-reported_JJ aspirin_NN use_NN
        would_MD be_VB different_JJ for_IN patients_NNS treated_VBN at_IN RPCI_NNP than_IN for_IN
        those_DT treated_VBN at_IN other_JJ facilities_NNS ._. We_PRP attempted_VBD to_TO minimize_VB
        this_DT source_NN of_IN bias_NN by_IN randomly_RB selecting_VBG controls_NNS from_IN a_DT
        large_JJ pool_NN of_IN eligible_JJ patients_NNS from_IN a_DT wide_JJ variety_NN of_IN
        diagnostic_JJ groups_NNS ._. Only_RB about_IN 50_CD %_NN of_IN eligible_JJ cases_NNS and_CC
        controls_NNS completed_VBD the_DT PEDS_NNP questionnaire_NN ,_, likely_JJ to_TO
        further_VB introduce_VB a_DT selection_NN bias_NN ._. We_PRP had_VBD no_DT way_NN to_TO
        ascertain_VB whether_IN those_DT that_WDT refused_VBD to_TO participate_VB
        differed_VBD with_IN respect_NN to_TO aspirin_NN use_NN ._. Despite_IN these_DT
        limitations_NNS ,_, it_PRP should_MD be_VB pointed_VBN out_RP that_IN numerous_JJ
        previous_JJ studies_NNS that_WDT have_VBP utilized_JJ the_DT PEDS_NNP database_NN ,_, and_CC
        faced_VBD the_DT same_JJ methodological_JJ issue_NN ,_, have_VBP consistently_RB
        replicated_VBN established_VBN epidemiological_JJ associations_NNS for_IN a_DT
        variety_NN of_IN cancer_NN sites_NNS [_NN 31_CD 32_CD 33_CD 34_CD 35_CD ]_NN ._. Further_RB ,_, as_IN
        mentioned_VBN above_IN ,_, smoking_NN and_CC family_NN history_NN of_IN pancreatic_JJ
        cancer_NN are_VBP two_CD of_IN the_DT few_JJ established_VBN risk_NN factors_NNS for_IN
        pancreatic_JJ cancer_NN [_NN 36_CD ]_NN ,_, and_CC they_PRP were_VBD found_VBN to_TO be_VB
        associated_VBN with_IN disease_NN risk_NN in_IN our_PRP$ data_NNS ._. Other_JJ limitations_NNS
        of_IN this_DT study_NN include_VBP the_DT potential_JJ biases_NNS inherent_JJ in_IN
        case-control_JJ studies_NNS ._.
        The_DT primary_JJ strengths_NNS of_IN our_PRP$ study_NN are_VBP the_DT different_JJ
        types_NNS of_IN exposure_NN variables_NNS and_CC size_NN ._. In_IN examining_VBG general_JJ
        use_NN ,_, as_RB well_RB as_IN frequency_NN and_CC duration_NN ,_, it_PRP is_VBZ possible_JJ to_TO
        see_VB which_WDT measure_NN of_IN aspirin_NN use_NN ,_, if_IN any_DT ,_, is_VBZ associated_VBN
        with_IN pancreatic_JJ cancer_NN risk_NN ,_, and_CC not_RB rely_VB solely_RB on_IN more_RBR
        general_JJ categorical_JJ designations_NNS like_IN regular_JJ vs_NNS ._.
        non-users_JJ ._. Further_RB ,_, the_DT rareness_NNS and_CC aggressive_JJ nature_NN of_IN
        this_DT cancer_NN makes_VBZ it_PRP difficult_JJ to_TO conduct_VB large_JJ
        retrospective_NN population_NN studies_NNS ._. Because_IN of_IN the_DT large_JJ
        number_NN of_IN patients_NNS seen_VBN at_IN the_DT Roswell_NNP Park_NNP Cancer_NNP
        Institute_NNP over_IN the_DT long_JJ study_NN period_NN (_( 1982_CD -_: 1998_CD )_) ,_, close_RB to_TO
        200_CD pancreatic_JJ cancer_NN patients_NNS were_VBD included_VBN in_IN the_DT
        analysis_NN ._.
      
      
        Conclusions_NNP
        To_TO summarize_VB ,_, in_IN this_DT hospital_NN based_VBD case-control_JJ study_NN
        of_IN pancreatic_JJ cancer_NN ,_, we_PRP found_VBD no_DT association_NN between_IN
        aspirin_NN use_NN and_CC risk_NN ._. Since_IN it_PRP is_VBZ widely_RB thought_VBN that_IN
        COX-_NNP 2_CD ,_, more_RBR so_RB than_IN COX-_NNP 1_CD ,_, may_MD play_VB a_DT role_NN in_IN neoplasia_NN ,_, it_PRP
        is_VBZ reasonable_JJ to_TO think_VB that_IN the_DT more_RBR effective_JJ drugs_NNS would_MD
        be_VB selective_JJ for_IN COX-_NNP 2_CD ._. These_DT agents_NNS address_VBP the_DT different_JJ
        physiologic_JJ roles_NNS of_IN the_DT two_CD COX_NNP enzymes_NNS as_RB well_RB as_IN reduce_VB
        adverse_JJ side_NN effects_NNS of_IN prolonged_JJ drug_NN use_NN [_NN 37_CD ]_NN ._.
        Nevertheless_RB ,_, as_IN discussed_VBN above_IN ,_, certain_JJ experimental_JJ and_CC
        population_NN studies_NNS [_NN 20_CD 21_CD 22_CD ]_NN do_VBP indicate_VBP that_IN drugs_NNS like_IN
        aspirin_NN ,_, which_WDT can_MD act_VB on_IN both_DT COX-_NNP 1_CD and_CC 2_CD ,_, may_MD play_VB a_DT role_NN
        in_IN prevention_NN and_CC therapy_NN of_IN pancreatic_JJ cancer_NN ._. Given_VBN the_DT
        biologic_JJ plausibility_NN for_IN a_DT potential_JJ chemopreventive_JJ
        effect_NN of_IN aspirin_NN and_CC other_JJ NSAIDs_NNP on_IN pancreatic_JJ cancer_NN
        risk_NN ,_, additional_JJ analytic_JJ epidemiological_JJ studies_NNS are_VBP
        needed_VBN to_TO further_VB explore_VB this_DT risk_NN association_NN ._. These_DT
        studies_NNS should_MD incorporate_VB more_RBR detailed_JJ information_NN on_IN
        aspirin_NN other_JJ NSAIDs_NNP ,_, especially_RB selective_JJ COX-_NNP 2_CD
        inhibitors_NNS ,_, in_IN order_NN to_TO allow_VB for_IN a_DT more_RBR comprehensive_JJ
        exposure_NN assessment_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        RJM_NNP and_CC KRH_NNP participated_VBD in_IN statistical_JJ analysis_NN and_CC
        drafting_VBG the_DT manuscript_NN ._. MCM_NNP participated_VBD in_IN study_NN design_NN
        and_CC manuscript_NN preparation_NN ._. KBM_NNP conceived_VBD of_IN the_DT study_NN and_CC
        participated_VBD in_IN its_PRP$ design_NN and_CC manuscript_NN preparation_NN ._.
      
    
  
